Article
Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine
Registro en:
DAMASCENO, Patricia Kauanna Fonseca et al. Kauanna FonsecaGenetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine. Frontiers in Cell and Developmental Biology, v. 8, Article 737, p. 1-24, Aug. 2020.
2296-634X
10.3389/fcell.2020.00737
Autor
Damasceno, Patricia Kauanna Fonseca
Santana, Thaís Alves de
Santos, Girlaine Café
Orge, Iasmim Diniz
Silva, Daniela Nascimento
Albuquerque, Juliana Fonseca
Golinelli, Giulia
Grisendi3, Giulia
Pinelli, Massimo
Santos, Ricardo Ribeiro dos
Dominici, Massimo
Soares, Milena Botelho Pereira
Resumen
Brazilian National Research Council (CNPq)/MS
grant number 443909/2018-0 and INOVA/FIOCRUZ grant
number VPPIS-001-FIO-18-70. Mesenchymal stem/stromal cells (MSCs) have been widely studied in the field of regenerative medicine for applications in the treatment of several disease settings. The therapeutic potential of MSCs has been evaluated in studies in vitro and in vivo, especially based on their anti-inflammatory and pro-regenerative action, through the secretion of soluble mediators. In many cases, however, insufficient engraftment and limited beneficial effects of MSCs indicate the need of approaches to enhance their survival, migration and therapeutic potential. Genetic engineering emerges as a means to induce the expression of different proteins and soluble factors with a wide range of applications, such as growth factors, cytokines, chemokines, transcription factors, enzymes and microRNAs. Distinct strategies have been applied to induce genetic modifications with the goal to enhance the potential of MCSs. This review aims to contribute to the update of the different genetically engineered tools employed for MSCs modification, as well as the factors investigated in different fields in which genetically engineered MSCs have been tested.